Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How would you manage asymptomatic osseous sarcoidosis of the lumbar spine without any other systemic involvement?

2
1 Answers

Mednet Member
Mednet Member
Pulmonology · Johns Hopkins Hospital

Some patients with sarcoidosis are found to have bone-related abnormalities. These are frequently incidental findings often detected as a phantom abnormality on PET or MR scan without corresponding X-ray or CT abnormality; this suggests they are foci of inflammation localized within bone marrow and ...

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

3
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Chicago

There are many effective medications for PsA out there now that don't have the risk of making their skin disease worse as is the case with HCQ. Patients are also less compliant with daily pills. To me, 1 in 10 is an unacceptably high number to flare their skin.When viewing through a historical lens,...

Do you offer adjuvant radiation therapy for a breast cancer patient with dermatomyositis?

3
2 Answers

Mednet Member
Mednet Member
Rheumatology · Emory University

This is an exceptionally important question for clinicians. I'm a little biased as I run an autoimmune Myositis Clinic, but here are my two cents: Paraneoplastic dermatomyositis (DM) is a fairly common occurrence (roughly about 15% of all DM cases, but up to 30-40% in some subtypes, such as adult pa...

How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?

2
1 Answers

Mednet Member
Mednet Member
Rheumatology · Ohio State University

This is a great question - part of cytokine release at syndrome includes joint pain. So my questions are: How far after? What was the reason for the CAR-T? These are vital questions to understand first. To that be said - the answers will determine if you give a one-and-done treatment or long-term....

What is your approach to working up diarrhea in an immunocompromised patient?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Mobile Medical Care Inc

Tough question and very common in clinical and research management. The approach is going to mirror any new complaint and start with a history. Diarrhea means many things to many patients/clinical trial subjects, so characterizing duration, frequency in a day, nocturnal events (diarrhea that occurs ...

Is there a role for hydroxychloroquine for secondary prevention in patients with APS without SLE?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

There are no prospective trials to answer this question. In one cross-sectional study (Erkan et al., PMID 12154210) there was a suggestion of a protective effect of hydroxychloroquine. However, patients were also on aspirin and it may be difficult to sort out which of these agents had the protective...

How would you manage a patient with stable axial spondyloarthritis who develops newly active IgA nephropathy?

2
2 Answers

Mednet Member
Mednet Member
Nephrology · Columbia University

Although the data are sparse, in general, the principles of treatment of IgAN in the setting of spondyloarthritis is similar to primary IgAN. BP targets <120/80 RAS inhibitors or sparsentan SGLT2 inhibitors If persistent proteinuria despite above, targeted-release budesonide or oral corticosteroids ...

What is your approach for an RA patient with lung cancer who is starting immunotherapy?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Johns Hopkins School of Medicine

How to manage the patient depends on how well controlled their RA is at the start of therapy and what kind of medication regimen they are on for their RA. If they are on csDMARDs and are stable we usually continue the csDMARDs with immunotherapy unless there is an objection with the oncologist (or i...

Do you prefer to taper rituximab by extending the interval between doses or decreasing the actual dose administered for RA patients who have achieved longstanding remission?

1
3 Answers

Mednet Member
Mednet Member
Rheumatology · Northwestern University Feinberg School of Medicine

My practice has generally been to extend the interval, albeit with careful observation of the patient's clinical status throughout the process. To begin with, my practice is to start with 2 doses of 1000 mg at initiation of therapy, and then a single dose of 1000 mg for subsequent courses of therapy...

What dose and duration of steroid therapy do you use in steroid responsive ILD?

1
1 Answers

Mednet Member
Mednet Member
Pulmonology · Cleveland Clinic

This is an extremely challenging question to answer as "steroid-responsive lung disease" encompasses a variety of formal and informal diagnoses as well as a variety of different clinical scenarios. Additionally, the dose and duration of corticosteroids would depend on patient factors and comorbid co...